IgG3 Fc

IgG3 Fc Molekülinformation

Englischer Name	Immunoglobulin G	Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	8	Target-Alias	Immunoglobulin G
Höchste Forschungs- und Entwicklungsphase	Approved

Englischer Name	Immunoglobulin G
Target-Alias	Immunoglobulin G
Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	8
Höchste Forschungs- und Entwicklungsphase	Approved

IgG3 Fc Produktliste

Attribut
Protein (3)Antibody (1)
Produktbibliothek
Online (4)
Spezies
Human (2)Mouse (2)
Etikett
Tag Free (2)Avi Tag (1)- (1)
Marker
Unconjugated (2)Biotin-labeled (1)HRP Labeled (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Vorbestellen/Bestellen
IG3-H5200	Human	HEK293	Human IgG3 Fc Protein, Tag Free (MALS & SPR verified)	In den Warenkorb legen
IG3-H8213	Human	HEK293	Biotinylated Human IgG3 Fc Protein, Avitag™ (MALS verified)	In den Warenkorb legen
IG3-HMY2179	Mouse	HEK293	HRP conjugated Monoclonal Anti-Human IgG3 Fc Antibody, Mouse IgG2a (2B7)	In den Warenkorb legen
IG3-M5214	Mouse	HEK293	Mouse IgG3 Fc Protein, Tag Free (MALS verified)	In den Warenkorb legen

Gesamtmenge4

IgG3 Fc Molekülhintergrund

Immunoglobulin G3 (IgG3) is a member of many immunoglobulin G developed and secreted by effective B cells. In wake of cutting by pepsin, IgG is divided into two F(ab)s with one antigen binding site and a high conserved Fc segment. The Fc segment bears a highly conserved N-glycosylation site. Ig gamma-3 chain C region (IgG3-Fc / IGHG3) contains two constant regions of IgG3 H chain (CH2, CH3).

IgG3 Fc Molekülalias

Ig gamma-3 chain C region,IgG,IgG3

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Ricefidase	KJ-103; KJ103	Phase 3 Clinical	Shanghai Bao Pharmaceuticals Co Ltd	Anti-Glomerular Basement Membrane Disease; Guillain-Barre Syndrome; Rejection of renal transplantation	Details
AT-02	AT-02	Phase 2 Clinical	Attralus Inc	Amyloidosis; Immunoglobulin Light-chain Amyloidosis	Details
JZB-34	AAFP; JZB-34	Phase 1 Clinical	Shanghai Kexin Biotech Co Ltd	Hypersensitivity	Details
Emicizumab biosimilar (Jushi Biopharmaceutical)	SYS6053; SYS-6053	Phase 1 Clinical	Jushi Biopharmaceutical Co Ltd	Hemophilia A; Hemorrhage	Details
S-1117	S-1117	Phase 1 Clinical	Seismic Therapeutics Inc	Immune System Diseases	Details
BHV-1300	BHV-1300	Phase 1 Clinical	Biohaven Pharmaceuticals Inc	Arthritis, Rheumatoid; Graves Disease	Details
HNSA-5487	HNSA 5487; HNSA-5487	Phase 1 Clinical	Hansa Biopharma Ab	Autoimmune Diseases; Neoplasms	Details
Anti-CD33/anti-FcgammaRI bispecific antibody (UCSD)		Phase 1 Clinical	University Of California San Diego	Leukemia, Myeloid, Acute	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Imlifidase	Mac-1	Approved	Hansamed Inc	Idefirix	EU	Rejection of renal transplantation	Hansa Biopharma Ab	2020-08-25	Guillain-Barre Syndrome; Kidney Diseases; Kidney Failure, Chronic; Purpura, Thrombotic Thrombocytopenic; Rejection of renal transplantation; Rejection of organ transplantation; Renal Insufficiency, Chronic	Details